EPIC Fail For Mast Therapeutics’ Lead Drug Sends Shares Into Freefall

 
• By Alexandra Shimmings

Shares in Mast Therapeutics dropped by more than 80% upon news that a Phase III trial of its lead product vepoloxamer in sickle cell disease had failed.

Sickle cell anemia, 3D illustration showing blood vessel with normal and deformated crescent-like red blood cells
• Source: Shutterstock, Kateryna Kon

More from Clinical Trials

More from R&D